Development and External Validation of a Nomogram for Predicting Cancer-Specific Survival of Non-Small Cell Lung Cancer Patients With Ipsilateral Pleural Dissemination

Wang, Zhenfan; Li, Hao; Liu, Taorui; Sun, Zewen; Yang, Fan; Jiang, Guanchao

doi:10.3389/fonc.2021.645486

Cited by 6 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified gender, drinking history, the ratio of CD4 + T/CD8 + T, along with TNM stage as independent factors for prediction via multivariate cox analysis. Most of these independent factors were consistent with a host of previous findings on risk factors for NSCLC (37)(38)(39). Subsequently, the above 4 predictors were integrated into a nomogram to calculate the risk probability of disease recurrence or metastasis tailored to each individual patient.…”

Section: Discussionsupporting

confidence: 72%

A validated nomogram integrating baseline peripheral T-lymphocyte subsets and NK cells for predicting survival in stage I–IIIA non-small cell lung cancer after resection

Xu¹,

Luo²,

Tian³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

A validated nomogram integrating baseline peripheral T-lymphocyte subsets and NK cells for predicting survival in stage I–IIIA non-small cell lung cancer after resection

Xu¹,

Luo²,

Tian³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…The National Comprehensive Cancer Network (NCCN) guidelines recommend surgical intervention in select cases of stage IV NSCLC with single brain or adrenal metastases but a primary tumor is otherwise T1-2, N0-1 or T3, N0 ( 3 ). Accumulating literatures suggesting that primary tumor resection (PTR) could improve survival for patients with stage IV NSCLC ( 4 – 7 ), particularly those with ipsilateral pleural dissemination ( 8 – 15 ), synchronous bone metastasis ( 16 , 17 ), and extrathoracic oligometastatic ( 7 , 18 – 20 ).…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Impact of Lymph Node Dissection on Primary Tumor Resection for Stage IV Non–Small Cell Lung Cancer: A Population-Based Study

Zhang

Cheng

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveSelected patients with stage IV non–small cell lung cancer (NSCLC) who underwent primary tumor resection have witnessed a survival benefit. Whether additional lymph node dissection (LND) would result in a better effect remain unknown. We investigated the prognostic impact of LND on patients with stage IV NSCLC who received primary tumor resection (PTR).MethodsPatients with stage IV NSCLC who underwent PTR were identified from the Surveillance, Epidemiology, and End Results database from 2004 to 2016. Propensity-score matching was performed to minimize the confounding effect, and lung cancer-specific survival (CSS) and overall survival (OS) were compared after matching. Multivariable Cox regression was used to identify prognostic factors and to adjust for covariates in subgroup analysis. The effect of the number of lymph nodes examined on the CSS was evaluated by repeating the Cox analysis in a binary method.ResultsA total of 4,114 patients with stage IV NSCLC who receive surgery met our criteria, of which 2,622 (63.73%) underwent LND and 628 patients were identified 1:1 in LND and non-LND groups after matching. Compared with the non-LND group, the LND group had a longer CSS (median: 23 vs. 16 months, p < 0.001) and OS (median: 21 vs. 15 months, p < 0.001). Multivariable regression showed that LND was independently associated with favorable CCS [hazard ratio (HR) = 0.78, 95% confidence interval (CI) 0.69–0.89, P < 0.001] and OS (HR = 0.79, 95% CI 0.70–0.89, P < 0.001). Subgroup analysis suggested that LND is an independent favorable predictor to survival in the surgical patients who were older age (>60 years old), female, T3-4, N0, and M1a stage and those who underwent sublobar resection. In addition, a statistically significant CCS benefit was associated with an increasing number of lymph nodes examined through 25 lymph nodes.ConclusionsLND with a certain range of lymph nodes number examined was associated with improved survival for patients with stage IV NSCLC who received primary tumor resection. The results may have implications for guidelines on lymph nodes management in selective advanced NSCLC for surgery.

show abstract

“…Pleural invasion is always seemed to be an independent risk factor and an important prognostic factor of NSCLC [ 23 ]. In the 8th edition of the TNM classification for NSCLC, if a tumor shows ipsilateral pleural dissemination, it increases the T descriptor from T1 to T2 and upstages a tumor from stage IA to stage IB, no matter how small the size is [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Background With the combination therapy of PD-1/PD-L1 antibody and antiangiogenic drugs used widely in clinic, a novel method to estimate the prognosis of patients is needed. We aimed to develop a nomogram to examine prognosis of anti-PD-1/PD-L1 antibody plus bevacizumab in non-small cell lung cancer (NSCLC) patients. Methods We developed a nomogram using the cohort involving 204 NSCLC patients who treated with immunotherapy and anti-angiogenesis therapy. The nomogram was validated under the same conditions in another cohort with 69 patients. Prognostic factors were analyzed by Cox regression analysis. The nomogram was internally validated using bootstrap resampling and then externally validated. Performance was assessed using concordance index, calibration curve and decision curve analysis. Clinical utility was evaluated using receiver operation characteristic curve. Results Pleural metastasis (P = 0.001, HR = 2.980, 95%CI 1.521–5.837), ANC (P < 0.001, HR = 5.139, 95%CI 2.081–12.691), ALC (P = 0.010, HR = 0.331, 95%CI 0.142–0.771), B cells (P = 0.005, HR = 0.329, 95%CI 0.151–0.714), Treg cells (P = 0.002, HR = 2.934, 95%CI 1.478–5.826) were independent prognostic factors. The calibration curves showed good consistency and the C-index of nomogram were 0.808, 0.741 in training and external validation cohort, respectively. The area under the curve (AUC) in receiver operation characteristic curves (ROC) are 0.833 (P < 0.001) and 0.908 (P < 0.001), respectively. Conclusion We build an accurate and convenient nomogram to predict long-time overall survival (OS) of NSCLC patients treated with PD-1/PD-L1 antibody and antiangiogenic drugs and validated this nomogram. The nomogram might be helpful to clinicians to estimate long-time OS of NSCLC patients treated with PD-1/PD-L1 antibody and antiangiogenic drugs.

show abstract

Development and External Validation of a Nomogram for Predicting Cancer-Specific Survival of Non-Small Cell Lung Cancer Patients With Ipsilateral Pleural Dissemination

Cited by 6 publications

References 40 publications

A validated nomogram integrating baseline peripheral T-lymphocyte subsets and NK cells for predicting survival in stage I–IIIA non-small cell lung cancer after resection

A validated nomogram integrating baseline peripheral T-lymphocyte subsets and NK cells for predicting survival in stage I–IIIA non-small cell lung cancer after resection

The Prognostic Impact of Lymph Node Dissection on Primary Tumor Resection for Stage IV Non–Small Cell Lung Cancer: A Population-Based Study

Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer

Contact Info

Product

Resources

About